98%
921
2 minutes
20
Animal-based developmental and reproductive toxicological studies involving skin exposure rarely incorporate information on skin permeation kinetics. For practical reasons, animal studies cannot investigate the many factors which can affect human skin permeation and systemic uptake kinetics in real-life scenarios. Traditional route-to-route extrapolation is based on the same types of experiments and requires assumptions regarding route similarity. Pharmacokinetic modeling based on skin physiology and structure is the most efficient way to incorporate the variety of intrinsic skin and exposure-dependent parameters occurring in clinical and occupational settings into one framework. Physiologically-based pharmacokinetic models enable the integration of available in vivo, in vitro and in silico data to quantitatively predict the kinetics of uptake at the site of interest, as needed for 21st century toxicology and risk assessment. As demonstrated herein, proper interpretation and integration of these data is a multidisciplinary endeavor requiring toxicological, risk assessment, mathematical, pharmaceutical, biological and dermatological expertise.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.reprotox.2015.10.001 | DOI Listing |
ACS Omega
September 2025
Centre of Artificial Intelligence Driven Drug Discovery, Faculty of Applied Science, Macao Polytechnic University, Macao SAR 999078, China.
Tyrosinase, a copper-dependent oxidase, plays a critical role in melanin biosynthesis and is a target in skin-whitening cosmetics. Conventional inhibitors like arbutin and kojic acid are widely used but suffer from cytotoxicity, instability, and inconsistent efficacy, highlighting the need for safer, more effective alternatives. In this study, two ligand-based machine learning models were developed: one to predict the biological activity of compounds and the other to estimate specific pIC values.
View Article and Find Full Text PDFEur J Pharm Biopharm
September 2025
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, PR China. Electronic address:
Iguratimod (IGU) is a novel anti-rheumatic drug, which has anti-inflammatory effects, inhibits bone destruction, and promotes bone formation. However, the gastrointestinal side-effects caused by oral tablets of IGU pose a challenge. This study aimed to develop an IGU transdermal patch for Rheumatoid Arthritis (RA) through ion-pair and chemical penetrant strategies to improve the therapeutic efficacy.
View Article and Find Full Text PDFJ Biomater Sci Polym Ed
September 2025
Department. of Pharmaceutics, Delhi Pharma Sciences and Research University (DPSRU)Govt of NCT of Delhi, New Delhi, India.
Chronic wounds infected with multidrug-resistant bacteria pose a significant therapeutic challenge, requiring biocompatible and effective interventions. This study presents a novel lignin-based nanoparticle spray for the localized delivery of curcumin, a natural anti-inflammatory and antimicrobial compound. Lignin, a sustainable polyphenolic biopolymer with inherent antioxidant and antimicrobial activities, was used both as a carrier and functional agent.
View Article and Find Full Text PDFACS Appl Mater Interfaces
September 2025
School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, U.K.
Tuberculosis (TB), caused by , remains a global health emergency, particularly in low- and middle-income countries. Despite effective pharmacotherapy, prolonged treatment, poor adherence, and drug resistance continue to hinder eradication. Isoniazid (ISZ), a first-line antitubercular drug, is effective but limited by high aqueous solubility and short half-life, necessitating daily administration and causing plasma fluctuations.
View Article and Find Full Text PDFInt J Pharm X
December 2025
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Tadalafil (TDLF), a Biopharmaceutics Classification System (BCS) Class II drug, exhibits poor aqueous solubility and extensive first-pass metabolism, which limits its therapeutic efficacy. We developed Phosal-based transethosomes (TrEthOs) to overcome these challenges, thereby enhancing transdermal delivery. A Box-Behnken design was employed to optimize the formulation by evaluating the effects of Phosal type, polyethylene glycol (PEG) 400 concentration, and cholesterol content.
View Article and Find Full Text PDF